Prime Medicine Inc (PRME) Stock Price, Quote & News

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accum...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 465 0013

Website: primemedicine.com

Address:

60 First Street, Cambridge, United States

DragonAlgo Mar. 20 at 9:47 PM

🐉 $PRME PUT — DragonAlgo® Signal Contract: PRME PUT Expiry: 2027-01-15 | Strike: $4.00 | Type: PUT Option Plan (premium): Entry: $1.60 Stop: $1.15 TP1: $2.08 TP2: $2.72 TP3: $3.84 🔗 https://dragonalgo.com

0 · Reply

StockMarketGuru Mar. 20 at 7:42 PM

$PRME I may have spoke too soon

0 · Reply

StockMarketGuru Mar. 20 at 3:54 PM

$PRME 🧐

0 · Reply

Mcnulty_jimmy Mar. 20 at 2:30 PM

$PRME Daily Deion

0 · Reply

Elamenape2 Mar. 20 at 2:06 PM

$PRME

0 · Reply

PorkchopSquats Mar. 19 at 6:50 PM

$PRME Daily candles. Not a prediction yet, just a potential IHS setup in the making. Downside room to $3.30 for it to remain valid.

1 · Reply

someguytrades Mar. 19 at 6:27 PM

$PRME do we trust it gang? I do like seeing oklo red, prime green, common sense day in the market

1 · Reply

StockMarketGuru Mar. 19 at 6:20 PM

$PRME

1 · Reply

FredGS Mar. 19 at 4:51 PM

$PRME First time I saw this. Don't woke my company! https://youtu.be/IMpczE6WDzQ?si=7TWm23K8s7ougujg

0 · Reply

FredGS Mar. 19 at 4:22 PM

$PRME With a company like this, the last thing you would ever want to see is a buyout. That would cap the upside potential. This company has the best tech of any biotech in existence.

1 · Reply

Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 8:00 AM EST - 18 days ago

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Feb 25, 2026, 8:00 AM EST - 24 days ago

Prime Medicine to Participate in Upcoming Investor Conferences

Jan 14, 2026, 2:16 PM EST - 2 months ago

Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:00 AM EST - 2 months ago

Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 1:29 PM EST - 2 months ago

Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond

Dec 7, 2025, 8:05 AM EST - 3 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Nov 25, 2025, 8:00 AM EST - 4 months ago

Prime Medicine to Present at 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 2:51 PM EST - 4 months ago

Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript

Nov 11, 2025, 8:00 AM EST - 4 months ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Nov 7, 2025, 10:21 AM EST - 4 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 7, 2025, 7:00 AM EST - 4 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 3, 2025, 8:01 AM EST - 4 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

Oct 30, 2025, 4:01 PM EDT - 5 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy

Sep 8, 2025, 5:38 PM EDT - 6 months ago

Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 8:07 PM EDT - 7 months ago

Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 1, 2025, 4:01 PM EDT - 8 months ago

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jul 30, 2025, 9:33 PM EDT - 8 months ago

Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 4:01 PM EDT - 8 months ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Jul 16, 2025, 8:10 AM EDT - 8 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Jul 16, 2025, 7:00 AM EDT - 8 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Jul 7, 2025, 4:45 PM EDT - 9 months ago

Prime Medicine: Pressing Forward With Lead Liver Targeting Indications

May 19, 2025, 8:31 AM EDT - 10 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

May 19, 2025, 8:30 AM EDT - 10 months ago

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

May 8, 2025, 8:00 AM EDT - 11 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 24, 2025, 8:00 AM EST - 1 year ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 12:26 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Nov 26, 2024, 5:10 AM EST - 1 year ago

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

BMY

Nov 21, 2024, 4:18 AM EST - 1 year ago

Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Sep 30, 2024, 12:17 PM EDT - 1 year ago

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Sep 30, 2024, 8:38 AM EDT - 1 year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

BMY

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline

May 13, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 12, 2024, 3:00 AM EDT - 2 years ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB

May 10, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

Apr 29, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

Mar 1, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 4:01 PM EST - 2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Jan 28, 2024, 8:11 AM EST - 2 years ago

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Jan 25, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Jan 25, 2024, 8:00 AM EST - 2 years ago

Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Jan 5, 2024, 8:00 AM EST - 2 years ago

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

DragonAlgo Mar. 20 at 9:47 PM

0 · Reply

StockMarketGuru Mar. 20 at 7:42 PM

$PRME I may have spoke too soon

0 · Reply

StockMarketGuru Mar. 20 at 3:54 PM

$PRME 🧐

0 · Reply

Mcnulty_jimmy Mar. 20 at 2:30 PM

$PRME Daily Deion

0 · Reply

Elamenape2 Mar. 20 at 2:06 PM

$PRME

0 · Reply

PorkchopSquats Mar. 19 at 6:50 PM

$PRME Daily candles. Not a prediction yet, just a potential IHS setup in the making. Downside room to $3.30 for it to remain valid.

1 · Reply

someguytrades Mar. 19 at 6:27 PM

$PRME do we trust it gang? I do like seeing oklo red, prime green, common sense day in the market

1 · Reply

StockMarketGuru Mar. 19 at 6:20 PM

$PRME

1 · Reply

FredGS Mar. 19 at 4:51 PM

$PRME First time I saw this. Don't woke my company! https://youtu.be/IMpczE6WDzQ?si=7TWm23K8s7ougujg

0 · Reply

FredGS Mar. 19 at 4:22 PM

$PRME With a company like this, the last thing you would ever want to see is a buyout. That would cap the upside potential. This company has the best tech of any biotech in existence.

1 · Reply

Publicola29 Mar. 19 at 2:32 PM

$PRME we need this "BMS also agreed to pay Prime up to $1.4 billion in development milestones including up to $185 million in preclinical milestones, more than $2.1 billion in commercialization milestones, as well as royalties on net sales."

0 · Reply

Mcnulty_jimmy Mar. 19 at 2:21 PM

$PRME Daily Deion

0 · Reply

Publicola29 Mar. 19 at 2:14 PM

$PRME I think for Prime Editing to reach its full potential they need to be acquired by a large company with endless funds like Lilly. They'd have the funds to enforce the patents against the copycats, and they'd have the IP to address 90% of genetic rare diseases. An endless pipeline of drugs. For Prime to do it themselves will require a lot of dilution unfortunately. I'll be along for the ride either way. So much potential, it can't be unnoticed by the big boys. Alan Reine will get them acquired.

1 · Reply

Publicola29 Mar. 19 at 11:40 AM

$PRME what am i missing that eli lilly doesnt just buy this company for $5B?

0 · Reply

DragonAlgo Mar. 19 at 11:37 AM

🐉 $PRME PUT — DragonAlgo® Signal Contract: PRME PUT Expiry: 2026-04-17 | Strike: $4.00 | Type: PUT Option Plan (premium): Entry: $0.73 Stop: $0.53 TP1: $0.95 TP2: $1.24 TP3: $1.75 🔗 https://dragonalgo.com

0 · Reply

PorkchopSquats Mar. 18 at 9:10 PM

$PRME Bought back 10k shares today at $3.57. May be a bit early but I’m not convinced this is going back to sub-$3.20 again. Volume has plummeted again after spiking hard on the recent run up to $4.70’s. We shall see.

1 · Reply

StockMarketGuru Mar. 18 at 8:02 PM

$PRME welp

1 · Reply

someguytrades Mar. 18 at 7:48 PM

$PRME easily the dumbest valuation in the market. Used to be $OKLO being the dumbest in the opposite direction. Biotech being in essentially a 6 year bear market because it stacked the bio bear with the tech bear has pushed it to some of the stupidest valuations in history while harboring the most significant IP in our lifetimes.

0 · Reply

Lawneverchase Mar. 18 at 7:36 PM

$PRME Back down to 3.20 load zone

1 · Reply

someguytrades Mar. 18 at 3:49 PM

$PRME prime challenge to not trade like the most retarded stock in the market, impossible

0 · Reply

Mcnulty_jimmy Mar. 18 at 2:35 PM

$PRME Daily Deion

0 · Reply

DragonAlgo Mar. 18 at 11:17 AM

🐉 $PRME CALL — DragonAlgo® Signal Contract: PRME CALL Expiry: 2026-04-17 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.10 Stop: $0.07 TP1: $0.13 TP2: $0.17 TP3: $0.24 🔗 https://dragonalgo.com

0 · Reply

Market Cap	635.54M
Revenue (ttm)	4.63M
Net Income (ttm)	-201.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,344.28%
Debt to Equity Ratio	0.00

Volume	6,010,400
Avg Vol	2,962,046
Day's Range	N/A - N/A
Shares Out	180.55M
Stochastic %K	7%
Beta	2.56
Analysts	Strong Sell
Price Target	$6.92